LEX Diagnostics

Executive Summary

LEX Diagnostics is a UK-based point-of-care molecular diagnostics company developing the LEX VELO system, a CLIA-waived PCR platform that delivers lab-quality results in under 10 minutes with minimal hands-on time. Founded in 2019 in Cambridge, the company aims to redefine rapid testing by combining high speed and sensitivity, targeting respiratory infections and expanding into other indications. The LEX VELO Respiratory Test can produce positive results in as little as 6 minutes, positioning it as a transformative tool for emergency departments, urgent care, and decentralized testing settings. Despite a strong technology value proposition, LEX Diagnostics remains a private, pre-revenue company with no disclosed funding rounds or commercial partnerships. Its success hinges on securing regulatory clearances (e.g., FDA 510(k) or CE marking), scaling manufacturing, and establishing distribution channels. The global demand for rapid point-of-care diagnostics provides a sizable market opportunity, but the company faces competition from established players. If LEX can execute on regulatory and commercial milestones, it has the potential to capture meaningful market share in the near-term.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for LEX VELO System70% success
• Q2 2026Series A or B Funding Round60% success
• Q4 2026Commercial Partnership with Diagnostic Distributor50% success